NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $5.39 -0.01 (-0.19%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CureVac Stock (NASDAQ:CVAC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CureVac alerts:Sign Up Key Stats Today's Range$5.38▼$5.4550-Day Range$3.23▼$5.6052-Week Range$2.37▼$5.72Volume748,606 shsAverage Volume994,750 shsMarket Capitalization$1.21 billionP/E Ratio5.86Dividend YieldN/APrice Target$6.83Consensus RatingHold Company Overview CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. Read More CureVac Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreCVAC MarketRank™: CureVac scored higher than 94% of companies evaluated by MarketBeat, and ranked 70th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageCureVac has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CureVac's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is 5.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.45.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is 5.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.71.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.72% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CureVac has recently decreased by 38.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-2.10 Percentage of Shares Shorted2.72% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CureVac has recently decreased by 38.10%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment0.03 News SentimentCureVac has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CureVac this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 2 people have added CureVac to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address CVAC Stock News HeadlinesCureVac (NASDAQ:CVAC) Stock Rating Lowered by UBS GroupJune 28, 2025 | americanbankingnews.comUBS Downgrades CureVac N.V. (CVAC)June 27, 2025 | msn.comBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…July 3 at 2:00 AM | Crypto 101 Media (Ad)$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)June 20, 2025 | globenewswire.comBioNTech SE Announces Acquisition of CureVac N.V.June 17, 2025 | tipranks.comM&A News: BioNTech Snaps Up CureVac in $1.25B Deal to Supercharge Cancer PipelineJune 14, 2025 | theglobeandmail.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of ShareholdersJune 13, 2025 | globenewswire.comCureVac stock soars about 30% after BioNTech agrees to acquire coJune 13, 2025 | finance.yahoo.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $3.41 at the beginning of 2025. Since then, CVAC stock has increased by 58.2% and is now trading at $5.3950. View the best growth stocks for 2025 here. How were CureVac's earnings last quarter? CureVac N.V. (NASDAQ:CVAC) issued its quarterly earnings results on Thursday, May, 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.08. The firm earned $0.94 million during the quarter, compared to the consensus estimate of $4.27 million. CureVac had a net margin of 35.44% and a trailing twelve-month return on equity of 30.89%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers. How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings5/22/2025Today7/03/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CVAC CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees880Year FoundedN/APrice Target and Rating Average Stock Price Target$6.83 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+26.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.92 Trailing P/E Ratio5.86 Forward P/E Ratio7.49 P/E GrowthN/ANet Income$175.50 million Net Margins35.44% Pretax Margin39.67% Return on Equity30.89% Return on Assets25.54% Debt Debt-to-Equity Ratio0.05 Current Ratio7.65 Quick Ratio7.64 Sales & Book Value Annual Sales$579.18 million Price / Sales2.09 Cash Flow$0.87 per share Price / Cash Flow6.20 Book Value$3.36 per share Price / Book1.60Miscellaneous Outstanding Shares224,340,000Free Float219,515,000Market Cap$1.21 billion OptionableOptionable Beta2.53 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:CVAC) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.